JPRN-UMIN000012350尚未招募2 期
Phase II study of eribulin with trasutuzumab for pretreated locally advanced / metastatic HER2-positive breast cancer - Phase II study of eribulin with trasutuzumab for pretreated locally advanced / metastatic HER2-positive breast cancer
agoya University0 个研究点目标入组 50 人开始时间: 2013年11月20日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •(1)Patients with active double cancer with less than 5years desease free intervals except for dissected carcinoma in situ or intramucosal cancer. (2)Patients with a past history of interstitial pneumonitis, pulmonary fibrosis or severe emphysema. (3)Patients diagnosed as having unstable angina, congestive heart failure, myocardial infarction, ventricular arrhythmia requiring medication within 6 months before registration. (4)Patients with uncontrolled complications(malignant hypertension,infection,hemorrhagic tendency,diabates) (5)Active infection or fever suspicious of infection (6)Severe renal dysfunction and liver dysfunction (jaundice) (7)History use of eribulin (8)Patients with uncontrollable brain metastases (9)HBs antigen positive (case of the anti-HBs or anti-HBc positive patients in HBs antigen negative, for adding precision inspection and administration of nucleic acid analog, do at the discretion of each facility) (10)Patients who were considered by the primary care physician to be inappropriate as subjects of this trial
研究者
相似试验
尚未招募
2 期
Phase II trial with eribulin and trastuzumab for advanced/recurrent HER2-positive breast cancerBreast cancerJPRN-UMIN000010844The University of Tokushima graduate school30
已完成
2 期
Prospective study of Eribulin plus Trastuzumab in patients with HER-2 positive metastatic breast cancer (KSCOG-BC06)HER2 positive metastatic breast cancerJPRN-UMIN000010761Kurume University School of Medicine Department of Surgery30
已完成
2 期
Combination therapy of Eribulin with Trastuzumab for HER2 positive metastatic breast cancer.HER2 positive metastatic breast cancerJPRN-UMIN000009296Setouchi Breast Project30
已完成
不适用
Combination therapy of Eribulin, Trastuzumab and Pertuzumab for the treatment of patients with previously treated advanced HER2-positive breast cancer.Breast cancerJPRN-UMIN000012018Mie University Hospital10
已完成
2 期
A phase II study of eribulin in combination with trastuzumab and pertuzumab as First-Line therapy for metastatic HER2-positive breast cancerFirst-Line therapy for metastatic HER2-positive breast cancer.JPRN-UMIN000021585Sairtama Breast Cancer Clinical Study Group (SBCCSG)16